diabetes type 2 diabetes
Conditions
Interventions
For this study, subjects will consume clenbuterol (20 microgram/capsule) or
placebo tablets twice daily (40 microgram/day) for a total period of 4 weeks
(2x 2 weeks).
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Caucasian; 2. Male sex; 3. Age: 18-30 years 4. BMI: 20-25 kg/m2; 5. Normal physical activity levels;
Exclusion criteria
Exclusion criteria: 1. Not meeting all inclusion criteria 2. Cardiovascular disease (determined by means of questionnaires, heart rate/blood pressure measurements and an ECG); 3. Respiratory diseases (including asthma, bronchitis and COPD); 4. Unstable body weight (weight gain or loss > 5 kg in the last three months); 5. Intention to lose or gain body weight (e.g. with caloric restriction or physical activity) 6. Excessive alcohol and/or drug abuse; 7. Hypokalaemia; 8. Anaemia; 9. Epilepsy; 10. Smoking; 11. Renal and/or liver insufficiency; 12. Participation in another biomedical study within 1 month before the first study visit, possibly interfering with the study results; 13. Medication use known to hamper subject*s safety during the study procedures; * 14. Subjects who do not want to be informed about unexpected medical findings; * 15. Subjects who do not want that their treating physician to be informed; 16. Inability to participate and/or complete the required measurements; 17. Participation in organised or structured physical exercise; 18. Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk; 19. Hyperthyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome parameter: - Insulin-stimulated peripheral glucose disposal (Rd) during the high-insulin infusion of the two-step hyperinsulinemic-euglycemic clamp | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters: - Skeletal muscle GLUT4 translocation Explorative objectives: - Body weight/composition - Plasma substrates - Heart rate and blood pressure - Insulin-mediated suppression of hepatic glucose production - (Sleeping) energy expenditure and substrate oxidation - Skeletal muscle glycogen and lipid content - Gene and protein expression in skeletal muscle - Femoral artery flow mediated dilation (FMD) | — |
Countries
Netherlands
Outcome results
None listed